ReviewInfectious disease reports2016
Tuberculosis Biomarkers: From Diagnosis to Protection.
Review in Infectious disease reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 4 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Abdominal tuberculosis in children: a systematic review on current advances.Pediatric surgery international · 2025Pooled it
- Tryptophan and Its Derived Metabolites as Biomarkers for Tuberculosis Disease: A Systematic ReviewIranian biomedical journal · 2024Pooled it
- MicroRNAs as diagnostic biomarkers for Tuberculosis: A systematic review and meta- analysis.Frontiers in immunology · 2022Pooled it
- Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults.International journal of mycobacteriologyPooled it
- Trial
- CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.PloS one · 2019Trial
- Review
- The Dual Immunoregulatory Role of CREB3L1 Underlying Latent and Severe Tuberculosis Clinical Manifestation.Immunology · 2026Article
- Triple-modality diagnosis of paucibacillary pulmonary tuberculosis: comparative accuracy of GeneXpert MTB/RIF, TB-DNA PCR, and T-SPOT.TB.Frontiers in medicine · 2026Article
- Review
- Disorders of gut microbiota and fecal-serum metabolic patterns are associated with pulmonary tuberculosis and pulmonary tuberculosis comorbid type 2 diabetes mellitus.Microbiology spectrum · 2025Article
- Exploration of plasma exosomal miR-122-5p and its related targets KNG1 and C3 in the diagnosis of drug-resistant tuberculosis.Scientific reports · 2025Article
- Adenosine Deaminase and Systemic Immune Inflammatory Index-A Biomarker Duet Signature of Pulmonary Tuberculosis Severity.Medicina (Kaunas, Lithuania) · 2025Observational
- RNA-Seq transcriptome profiling reveals distinct immune response landscapes to identifying inflammation-related diagnostic markers in latent endometrial tuberculosis.Scientific reports · 2025Article
- Bridging science and policy in tuberculosis treatment through innovations in precision medicine, drug development, and cohort research: a narrative review.Ewha medical journal · 2025Review
- Etiological Insights and the Role of Individual Factors in Infectious Spondylodiscitis.Infectious disease reports · 2025Article
- Review
- Decoding the hidden realm: Molecular pioneering unravelling osteoarticular tuberculosis diagnosis.Journal of clinical orthopaedics and trauma · 2024Article
- Correlation of serum Adenosine Deaminase levels with microbiological parameters in Pulmonary Tuberculosis.Indian journal of clinical biochemistry : IJCB · 2024Article
- Polyketide Synthase 13 (Pks13) Inhibition: A Potential Target for New Class of Anti-tubercular Agents.Current topics in medicinal chemistry · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New approaches to control tuberculosis (TB) worldwide are needed. In particular, new tools for diagnosis and new biomarkers are required to evaluate both pathogen and host key elements of the response to infection. Non-sputum based diagnostic tests, biomarkers predictive of adequate responsiveness to treatment, and biomarkers of risk of developing active TB disease are major goals. Here, we review the current state of the field. Although reports on new candidate biomarkers are numerous, validation and independent confirmation are rare. Efforts are needed to reduce the gap between the exploratory up-stream identification of candidate biomarkers, and the validation of biomarkers against clear clinical endpoints in different populations. This will need a major commitment from both scientists and funding bodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.